Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,706 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 4, 2026, 10:41 PM EDT
Recruiting Phase 4 Interventional

CLOZAPINE Response in Biotype-1

NCT04580134
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

NCT02968121
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole, OPDC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Garden Grove, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Cognitive Remediation and Social Skills Training in Schizophrenia

NCT00223535
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Cognitive Remediation, Social Skills Training
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Sep 4, 2026, 10:41 PM EDT
Withdrawn Not applicable Interventional

Lifestyle MIND- Feasibility of Wait-list Control

NCT06384521
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Serious Mental Illness, Schizophrenia, Major Depression, Bipolar Disorder
Interventions
Lifestyle MIND
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional

White Matter Plasticity in Schizophrenia

NCT06641297
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Music video game
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
15 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435
View directory record Official record
Conditions
Schizophrenia
Interventions
EN3342
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2

NCT03896438
View directory record Official record
Conditions
Transcranial Direct Current Stimulation, Schizophrenia, Schizoaffective Disorder
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

NCT03238326
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
17
States / cities
Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Cognitive Remediation in 22q11DS

NCT01781923
View directory record Official record
Conditions
22q11.2 Deletion Syndrome, Velo-Cardio-Facial Syndrome
Interventions
Cognitive remediation program, Small group social skills training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
11 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 4, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

NCT03870880
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 4, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing

NCT01602263
View directory record Official record
Conditions
Aphasia, Autism, Schizophrenia
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 4, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01425684
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
12 Years to 80 Years
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Not applicable Interventional

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCT06486948
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 4, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia

NCT00001920
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCT04369391
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856 150 mg, Placebo, moxifloxacin 400 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 4, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

NCT02194933
View directory record Official record
Conditions
Schizophrenia With Impulsivity
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 4, 2026, 10:41 PM EDT
Terminated No phase listed Observational

Screening for Childhood-Onset Psychotic Disorders

NCT00049738
View directory record Official record
Conditions
Childhood Onset Psychotic Disorders, Schizophrenia, Psychosis, Psychotic Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 4, 2026, 10:41 PM EDT
Terminated Not applicable Interventional Results available

Treating Refractory Schizophrenia With rTMS

NCT02242578
View directory record Official record
Conditions
Schizophrenia
Interventions
1 Hz rTMS, 10 Hz rTMS
Device
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 4, 2026, 10:41 PM EDT